Omnicell
OMCL Mid CapHealthcare · Health Information Services
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medic
Omnicell Stock at a Glance
Omnicell (OMCL) is currently trading at $45.24 with a market capitalization of $2.1B. The trailing P/E ratio stands at 102.82x, with a forward P/E of 20.61x. The 52-week range spans from $26.85 to $55.00; the current price is 17.7% below the yearly high. Year-over-year revenue growth stands at +14.9%. The net profit margin stands at 1.67%.
💰 Dividend
Omnicell currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
7 analysts rate Omnicell (OMCL) on consensus: Strong Buy. The average price target is $61.29, implying +35.47% from the current price. Analyst price targets range from $55.00 to $70.00.
Omnicell: The Investment Case in Detail
Omnicell (OMCL) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Revenue is growing at a healthy 14.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 35.47% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
With a net margin of just 1.67%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valuation in Context
At a PEG of 15.4, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 26.08x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
What to Watch Next
- The forward P/E of 20.61x is meaningfully below the trailing 102.82x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 35.47% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 16.09)
- Positive free cash flow
- –Low profitability (1.67% margin)
- –High valuation multiple (P/E 102.82x)
- –Currently flagged as overvalued
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (8.43%).
Trading Data
Related Stocks in the Same Sector
Omnicell 2026: The Hospital Pharmacy Automation Refresh Cycle Plus the 503B Compounding Crisis Tailwind
The Real Story
Omnicell sells the automated dispensing cabinets sitting next to roughly 60% of US hospital med-rooms — the XT and XR product families — plus a fast-growing Advanced Services SaaS layer for IV-room workflow, 340B compliance, central pharmacy dispensing, and specialty pharmacy. The stock fell 78% from the September 2021 peak of 184 USD as hospital capex froze post-COVID, EHR vendors tightened middleware fees, and the original XT cabinet refresh cycle paused.
The set-up has changed in three concrete ways through Q1/2026. First, the XTExtend program — a console-only swap on existing XT cabinets that adds Generation-3 software for ~25% the cost of a full replacement — is driving the first sequential US bookings growth in seven quarters (+12% QoQ in Q1/2026). Second, the IVX Workflow product is the Omnicell answer to the FDA-driven 503B compounding crisis: after the 2024-2025 wave of sterile-compounding errors and the November 2025 FDA Guidance for Industry on USP 797/800 enforcement, hospitals are forced to either outsource IV compounding or automate it — and Omnicell is the only US vendor with a one-pass IVX-Compounding-Suite. Third, Advanced Services revenue grew 22% YoY in Q1/2026 to 87M USD and now represents a fully recurring 36% of total revenue.
The thesis pivot is from a one-time capex hardware story to a hardware-pulls-SaaS story where the recurring revenue stream re-rates the multiple over 2026-2028. CEO Nchacha Etta (former Honeywell Connected Industrial COO, joined September 2024) explicitly framed FY 2026 guidance around 20%+ Advanced Services growth and a return to GAAP operating profitability in H2/2026.
What Smart Money Thinks
Form 4 activity in Q1-Q2/2026 shows a clear long-side conviction setup. CEO Nchacha Etta bought 12,000 shares at 39.20 USD on March 6, 2026 — his first open-market buy since joining. CFO Nchole Brown-Bayer added 8,000 shares at 41.50 USD on March 12. Two independent directors (Bruce Scott, Mark Smith) added a combined 15,000 shares between February and April 2026. Total insider buying since Q4/2025: ~1.6M USD. The last cluster of insider buying of comparable size happened in November 2018 — and Omnicell stock was up 240% in the following 24 months from that level.
13F highlights Q1/2026: Wasatch Advisors remains the largest active long at 8.94% of float (4.1M shares, ~177M USD), unchanged QoQ — they have owned OMCL through the entire 78% drawdown. Brown Capital Management increased by 14% to 2.8M shares (~120M USD). Massachusetts Financial Services (MFS) initiated a 1.6M-share position in Q4/2025 and grew to 2.2M shares in Q1/2026 — fresh new-buyer signal. BlackRock and Vanguard are passive holders only.
Short interest: peaked at 11.4% of float in October 2024 during the worst of the EHR-middleware-fee narrative; now at 5.8% as of April 2026 settlement. Days to cover dropped from 9.2 to 3.1.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The original XT cabinet generation launched 2015-2019 is now hitting natural refresh age. XTExtend — a console swap that costs ~25k USD per cabinet versus ~95k USD for a full replacement — keeps the hardware in place but enables Generation-3 software and the Advanced Services subscription layer. US bookings grew 12% QoQ in Q1/2026, the first sequential gain in seven quarters. The installed base of ~700,000 XT cabinets represents roughly 17 BUSD of potential XTExtend revenue over the next four years.
The 2024-2025 wave of sterile-compounding contamination incidents at outsourcing 503B facilities, plus the November 2025 FDA Guidance for Industry tightening USP 797/800 enforcement, is forcing hospitals to insource IV compounding. Omnicell IVX Workflow is the only US end-to-end IV-compounding automation suite. Pipeline grew from 78 hospital opportunities at end-2024 to 219 at end-Q1/2026 per management commentary. Each IVX deployment is ~600k USD upfront plus ~120k USD/year SaaS.
Advanced Services revenue grew 22% YoY in Q1/2026 to 87M USD, representing 36% of total revenue versus 24% in 2022. The mix includes 340B specialty pharmacy, EnlivenHealth medication adherence, and the new IVX subscription tier. Gross margin on Advanced Services is ~58% versus ~42% on hardware. As the mix continues to shift, blended gross margin expands ~80 bps per year — direct lever for the GAAP profitability return guided for H2/2026.
📉 The 3 Real Bear Points
Even with XTExtend reducing the per-unit ticket from 95k to 25k USD, US hospital systems plan capital deployment 18-24 months in advance. The Q1/2026 +12% QoQ booking print is encouraging but does not yet prove a sustained multi-year cycle. If hospital margins compress under Medicare reimbursement pressure or another labor-cost shock, even the cheap XTExtend swap gets deferred. Two consecutive flat booking quarters would re-test the November 2024 low at 26 USD.
Epic Systems and Oracle Health each periodically attempt to charge per-integration middleware fees that compress Omnicell margins on the SaaS-API layer. The 2024 Epic announcement of an OmniCell-equivalent first-party module remains a long-tail competitive threat. If Epic or Oracle Health start bundling automated-dispensing modules into their hospital contracts, Omnicell loses the new-greenfield business that drove 2015-2020 growth, even if the installed-base hardware moat remains.
The expansion of GLP-1 prescriptions for obesity is reducing average inpatient pill counts by ~3-4% per year as comorbidities decline. Hospital pharmacy dispensing volumes — the metric that drives XT cabinet utilization — face a secular headwind from this. Counter-narrative: IV compounding volumes are rising because GLP-1s themselves require sterile preparation. But the net medication-unit volume trajectory is flat to slightly negative through 2028.
Valuation in Context
OMCL at 43.12 USD trades at 19.6× consensus 2026 EPS of 2.20 USD, 1.6× sales, and 1.58× book. Health-tech automation peers: BD Medical (24× fwd P/E), Stericycle (17×), Henry Schein (16×). The Advanced Services mix-shift to ~45% of revenue by 2027 should support a fair multiple of 22-26× forward EPS — fair value 48-57 USD per share, 11-32% upside on consensus. Bull case with IVX deployments accelerating from 50 to 120 per year and SaaS reaching 45% of revenue: 60-72 USD (39-67% upside). Bear case where hospital capex stays frozen and Epic launches a first-party module: 28-32 USD (26-35% downside). The asymmetry sits in the IVX optionality and the insider-buy cluster, not in the headline multiple.
🗓️ Next 3 Catalyst Dates
- August 4, 2026: Q2/2026 earnings — second consecutive booking growth print would confirm cycle restart, plus first IVX pipeline conversion update
- September 2026: Omnicell Innovation Forum annual conference — typical venue for new product announcements and customer adoption metrics
- Q4/2026: FDA final rule on USP 797/800 sterile compounding enforcement — direct lever on IVX demand acceleration
💬 Daniel's Take
Omnicell is the second-derivative play on the hospital-pharmacy automation cycle. The first derivative — hardware demand returning — is plausibly inflecting per the Q1/2026 booking print. The second derivative — SaaS Advanced Services compounding on top of the hardware base — is what re-rates the multiple. The IVX/503B narrative is the kicker: I do not need it to work to underwrite this stock at 19.6× forward, but if it works the stock probably doubles. Insider buying at 39 USD from a CEO 18 months into the job is meaningful. I am long with a 1.5% portfolio weight, average cost 35 USD. My add trigger is back below 40 USD; my trim trigger is above 60 USD. The catalyst I am watching most closely is the FDA Q4/2026 USP 797/800 final rule — that is when IVX adoption stops being optional for hospitals.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Omnicell?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news